1,3-二氢-1-羟基-2,1-色氨酸-6-甲胺 | 1262279-06-0

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1,3-二氢-1-羟基-2,1-色氨酸-6-甲胺
• 中文别名: 6-(氨基甲基)苯并[C][1,2]氧杂硼醇-1(3H)-醇
• 英文名称: 6-(aminomethyl)benzo[c][1,2]oxaborol-1(3H)-ol
• 英文别名: (1-hydroxy-3H-2,1-benzoxaborol-6-yl)methanamine
• CAS: 1262279-06-0
• 化学式: C₈H₁₀BNO₂
• 分子量: 162.984
• InChiKey: BZQYHQXQCMJSLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.64
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,3-二氢-1-羟基-2,1-色氨酸-6-甲胺 、 生成 (2S,4R)-4-[(7-chloro-4-methoxy-1-isoquinolyl)oxy]-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]-1-[(2S)-2-[(1-hydroxy-3H-2,1-benzoxaborol-6-yl)methylcarbamoylamino]-3,3-dimethyl-butanoyl]pyrrolidine-2-carboxamide
  参考文献：
  名称：

  Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties

  摘要：

  We have synthesized and evaluated a new series of acyclic P4-benzoxaborole-based HCV NS3 protease inhibitors. Structure-activity relationships were investigated, leading to the identification of compounds 5g and 17 with low nanomolar potency in the enzymatic and cell-based replicon assay. The linker-truncated compound 5j was found to exhibit improved absorption and oral bioavailability in rats, suggesting that further reduction of molecular weight and polar surface area could result in improved drug-like properties of this novel series. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.006
• 作为产物：
  描述：

  3-溴-4-(羟基甲基)苯甲腈 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 1,3-二氢-1-羟基-2,1-色氨酸-6-甲胺
  参考文献：
  名称：

  PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

  摘要：

  This disclosure provides compounds, compositions, and methods to treat medical disorders, such as complement-mediated disorders, including complement C1s-mediated disorders.

  公开号：

  WO2024044098A2

文献信息

• [EN] BORON-CONTAINING SMALL MOLECULES<br/>[FR] PETITES MOLÉCULES CONTENANT DU BORE
  申请人：ANACOR PHARMACEUTICALS INC

  公开号：WO2017151489A1

  公开（公告）日：2017-09-08

  Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed.

  化合物、药物配方和治疗细菌感染的方法被披露。
• [EN] BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF<br/>[FR] INHIBITEURS DES POMPES À EFFLUX BACTÉRIENNES POLYBASIQUES CONTENANT DU BORE ET UTILISATIONS THÉRAPEUTIQUES DE CES DERNIERS
  申请人：REMPEX PHARMACEUTICALS INC

  公开号：WO2012109164A1

  公开（公告）日：2012-08-16

  Disclosed herein are polybasic bacterial efflux pump inhibitors containing boronic acid functionality and their methods of synthesis, methods of use, and pharmaceutical compositions. Some embodiments include methods of treating or preventing a bacterial infection by co¬ administering to a subject infected with bacteria or at risk of infection with bacteria the efflux pump inhibitor with another anti-bacterial agent.

  本文披露了含硼酸功能的多碱性细菌外流泵抑制剂及其合成方法、使用方法和药物组合物。一些实施例包括通过向感染细菌或有细菌感染风险的受试者共同给予外流泵抑制剂和另一种抗菌剂的方法来治疗或预防细菌感染。
• BORON-CONTAINING SMALL MOLECULES
  申请人：Eli Lilly and Company

  公开号：US20130131017A1

  公开（公告）日：2013-05-23

  This invention provides novel compounds, methods of using the compounds, and pharmaceutical compositions containing the compounds.

  这项发明提供了新颖的化合物，使用这些化合物的方法，以及含有这些化合物的药物组合物。
• Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide
  作者：Yong-Kang Zhang、Jacob J. Plattner、Eric E. Easom、Tsutomu Akama、Yasheen Zhou、W. Hunter White、Jean M. Defauw、Joseph R. Winkle、Terry W. Balko、Jianxin Cao、Zhixin Ge、Jianzhang Yang

  DOI：10.1016/j.bmcl.2016.04.093

  日期：2016.7

  Novel isoxazoline amide benzoxaboroles were designed and synthesized to optimize the ectoparasiticide activity of this chemistry series against ticks and fleas. The study identified an orally bioavailable molecule, (S)-N-((1-hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)methyl)-2-methyl-4-(5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)benzamide (23), with a favorable

  设计并合成了新型异恶唑啉酰胺苯并恶唑，以优化该化学系列对tick和跳蚤的杀外寄生虫活性。该研究确定了一种口服生物可利用的分子，（S）-N -（（1-羟基-3,3-二甲基-1,3-二氢苯并[c] [1,2]氧杂硼-6-基）甲基）-2-甲基-4-（5-（3,4,5-三氯苯基）-5-（三氟甲基）-4,5-二氢异恶唑-3-基）苯甲酰胺（23），在犬中具有良好的药效学特征（C max  = 7.42 ng / mL；T max  = 26.0 h；终末半衰期t 1/2  = 127 h）。化合物23，一种发展中的候选药物，在治疗后24小时内显示出100％的治疗效果，单次口服后第30天对美国的狗虱（Dermacentor variabilis）的残留功效为97％，对猫蚤（Ctenocephalides felis）的残留功效为98％剂量为25 mg / kg。
• BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Glinka Tomasz

  公开号：US20130316943A1

  公开（公告）日：2013-11-28

  Disclosed herein are polybasic bacterial efflux pump inhibitors containing boronic acid functionality and their methods of synthesis, methods of use, and pharmaceutical compositions. Some embodiments include methods of treating or preventing a bacterial infection by co-administering to a subject infected with bacteria or at risk of infection with bacteria the efflux pump inhibitor with another anti-bacterial agent.

  本文披露了含有硼酸官能团的多碱性细菌外排泵抑制剂及其合成方法、使用方法和制药组合物。其中一些实施例包括通过向感染细菌或有细菌感染风险的受试者联合给予外排泵抑制剂和另一种抗菌剂来治疗或预防细菌感染的方法。